Mercado cerrado -
Otros sitios de cotización
|
Después de cerrar 23:11:37 | |||
732,2 USD | -1,81 % | 728,5 | -0,50 % |
Resumen de negocios
- endocrinología (57,7%): productos para el tratamiento de la osteoporosis, la diabetes y los problemas de crecimiento;
- oncología (19,5%);
- enfermedades inmunológicas (11,1%);
- neurología (8,4%): principalmente medicamentos utilizados en el tratamiento de la depresión y la esquizofrenia;
- otros (3,3%).
Las ventas netas se distribuyen geográficamente del siguiente modo: Estados Unidos (63,9%), Europa (18,1%), Japón (4,9%), China (4,5%) y otros (8,6%).
Número de empleados: 43 000
Ventas por actividad
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
Human Pharmaceutical Products
100,0
%
| 28 541 | 100,0 % | 34 124 | 100,0 % | +19,56 % |
Ventas por región
USD en millones | 2022 | Peso | 2023 | Peso | Delta |
---|---|---|---|---|---|
United States
63,9
%
| 18 190 | 63,7 % | 21 791 | 63,9 % | +19,80 % |
Europe
18,1
%
| 4 299 | 15,1 % | 6 175 | 18,1 % | +43,62 % |
Other Foreign Countries
8,6
%
| 2 852 | 10,0 % | 2 946 | 8,6 % | +3,30 % |
Japan
4,9
%
| 1 747 | 6,1 % | 1 673 | 4,9 % | -4,28 % |
China
4,5
%
| 1 453 | 5,1 % | 1 540 | 4,5 % | +5,98 % |
Directores
Directores | Puesto | Edad | Desde |
---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 01/01/96 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 01/01/01 |
Ruth Gimeno
PSD | President | - | - |
Diogo Rau
CTO | Chief Tech/Sci/R&D Officer | - | 17/05/21 |
David Hyman
CTO | Chief Tech/Sci/R&D Officer | - | 16/10/23 |
Alonzo Weems
CMP | Compliance Officer | - | 01/01/97 |
Chief Tech/Sci/R&D Officer | 50 | 01/01/18 | |
Corporate Officer/Principal | - | 01/01/05 | |
Ilya Yuffa
PRN | Corporate Officer/Principal | 49 | - |
Ronald DeMattos
PRN | Corporate Officer/Principal | - | - |
Administradores
Administradores | Puesto | Edad | Desde |
---|---|---|---|
Director/Board Member | 63 | 25/01/21 | |
Ralph Alvarez
BRD | Director/Board Member | 67 | 01/04/09 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 01/01/05 |
Juan Luciano
BRD | Director/Board Member | 62 | 01/02/16 |
William Kaelin
BRD | Director/Board Member | 66 | 04/06/12 |
David Ricks
CEO | Chief Executive Officer | 56 | 01/01/96 |
Jamere Jackson
BRD | Director/Board Member | 54 | 01/10/16 |
Director/Board Member | 52 | 12/12/11 | |
Marschall Runge
BRD | Director/Board Member | 69 | 01/09/13 |
Karen Walker
BRD | Director/Board Member | 62 | 01/12/18 |
Clase de acciones
Vote | Quantity | Flotante | Autocontrol | Total Float | |
---|---|---|---|---|---|
Acción A | 1 | 951 168 100 | 949 200 653 ( 99,79 %) | 402 000 ( 0,0423 %) | 99,79 % |
Participaciones
Nombre | Acciones | % | Valoración |
---|---|---|---|
IMMUNOCORE HOLDINGS PLC 6.25% | 2 548 145 | 6.25% | 165 629 425 $ |
8 084 411 | 6.83% | 50 324 488 $ | |
PROQR THERAPEUTICS N.V. 16.55% | 13 371 562 | 16.55% | 30 620 877 $ |
4 000 000 | 9.40% | 26 840 000 $ | |
21 776 804 | 7.60% | 11 630 773 $ | |
AC IMMUNE SA 3.64% | 3 615 328 | 3.64% | 10 701 371 $ |
125 405 | 1.91% | 1 700 492 $ |
Información de la empresa
Empresas del grupo
Nombre | Categoría y sector |
---|---|
Eli Lilly SA
Eli Lilly SA Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly SA is a Swiss company that manufactures medicines. The private company is based in Vernier, Switzerland. |
Pharmaceuticals: Major
|
Kinsale Financial Services
| |
ELI Lilly & Company (India) Pvt Ltd.
ELI Lilly & Company (India) Pvt Ltd. Pharmaceuticals: MajorHealth Technology ELI Lilly & Company (India) Pvt Ltd. manufactures and markets pharmaceutical products. The firm's products treat diabetes, gastric cancer, lung cancer, osteoporosis, rheumatoid arthritis, men's health and growth-hormone deficiency. The company was founded in 1993 and is headquartered in Gurgaon, India. |
Pharmaceuticals: Major
|
Lilly Ventures Fund I LLC
Lilly Ventures Fund I LLC Investment ManagersFinance Lilly Ventures Fund I LLC seeks investment opportunities located in the North American and European regions. The fund targets companies operating in the fields of biotechnology, medical technology and healthcare IT. It provides financing for early stage capital requirements. |
Investment Managers
|
Eli Lilly Export SA (Switzerland)
Eli Lilly Export SA (Switzerland) Medical DistributorsDistribution Services Part of Eli Lilly & Co., Eli Lilly Export SA is a pharmaceutical company based in Vernier, Switzerland. The Swiss company combines care with research to develop innovative solutions for a better life worldwide. |
Medical Distributors
|
Eli Lilly Group Pension Trustees Ltd.
Eli Lilly Group Pension Trustees Ltd. Financial ConglomeratesFinance Part of Eli Lilly & Co., Eli Lilly Group Pension Trustees Ltd. operates as a British dormant company. The private company is based in Basingstroke, UK. |
Financial Conglomerates
|
Eli Lilly (Suisse) SA
| |
Eli Lilly Vostok SA
| |
Eli Lilly Services India Pvt Ltd.
Eli Lilly Services India Pvt Ltd. Pharmaceuticals: MajorHealth Technology Part of Eli Lilly & Co., Eli Lilly Services India Pvt Ltd. is an Indian company that discovers, develops, manufactures and sells pharmaceutical products. The private company is based in Bangalore, India and was founded in 2015. |
Pharmaceuticals: Major
|
Ventas por región
Revisiones del BPA
Varia. 1 de ene. | Capi. | |
---|---|---|
+25,61 % | 672 mil M | |
+25,87 % | 570 mil M | |
-5,24 % | 360 mil M | |
+16,49 % | 321 mil M | |
+8,28 % | 300 mil M | |
+7,09 % | 217 mil M | |
-9,12 % | 204 mil M | |
+5,01 % | 199 mil M | |
-8,75 % | 149 mil M | |
-5,21 % | 147 mil M |
- Bolsa de valores
- Acciones
- Acción LLY
- Empresa Eli Lilly and Company